Prime, Bristol Myers Squibb
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb (NYSE:BMY), which includes a $55M equity investment. Under the deal, Prime (PRME) will receive $55M upfront and the $55M investment.
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is rarely straightforward.
Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb
Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY)
Bristol, Prime Medicine in deal to develop T-cell therapies
Prime Medicine (NASDAQ:PRME) and Bristol Myers Squibb (NYSE:BMY) will work together on the development of next-generation ex vivo T-cell therapies. The deal calls for Prime Medicine to design optimized Prime Editor reagents for several targets.
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline
Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more than $3.
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company focuses on CGD programs and expects trial data in 2025.
Prime Medicine Unveils Strategically Focused Pipeline
Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime ...
FierceBiotech6h
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline
Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...
STAT4h
A radiopharmaceuticals startup raises $175 million
RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.
ENDPOINTS NEWS6h
Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers
Prime Medicine announced Monday morning that it is cutting its pipeline, and it signed a T cell therapy partnership with ...
precisionmedicineonline2h
Prime Medicine Pipeline Prioritization, Licensing Deal With BMS to Fund Operations Into 2026
The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Prime Medicine, Inc.
bovnews1d
The PRME Stock Mystery: Why Did PRME Plunge Today?
On Friday, Prime Medicine Inc (PRME) stock saw a decline, ending the day at $3.46 which represents a decrease of $-0.10 or -2.81% from the prior close of $3.56. The stock opened at $3.62 and touched a ...